[{"address1": "9708 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 243 1201", "fax": "301 738 2137", "website": "https://www.glycomimetics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Mr. Harout  Semerjian", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1126090, "exercisedValue": 0, "unexercisedValue": 465102}, {"maxAge": 1, "name": "Ms. Rachel K. King", "age": 64, "title": "Co-Founder & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian M. Hahn", "age": 49, "title": "Senior VP & CFO", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 822117, "exercisedValue": 0, "unexercisedValue": 98649}, {"maxAge": 1, "name": "Dr. Edwin  Rock M.D., Ph.D.", "age": 62, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 677399, "exercisedValue": 0, "unexercisedValue": 101250}, {"maxAge": 1, "name": "Ms. Stephanie R. Irish CPA", "age": 52, "title": "Vice President of Accounting", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christian B. Dinneen-Long", "title": "General Counsel & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bruce  Johnson", "age": 55, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chinmaya  Rath", "age": 46, "title": "Senior VP & Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shantha  Tyavanagimatt Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.28, "open": 2.29, "dayLow": 2.15, "dayHigh": 2.3577, "regularMarketPreviousClose": 2.28, "regularMarketOpen": 2.29, "regularMarketDayLow": 2.15, "regularMarketDayHigh": 2.3577, "beta": 2.193, "forwardPE": -4.8, "volume": 875938, "regularMarketVolume": 875938, "averageVolume": 408417, "averageVolume10days": 690420, "averageDailyVolume10Day": 690420, "bid": 2.11, "ask": 2.2, "bidSize": 100, "askSize": 100, "marketCap": 139212864, "fiftyTwoWeekLow": 1.11, "fiftyTwoWeekHigh": 3.53, "priceToSalesTrailing12Months": 13921.286, "fiftyDayAverage": 2.8336, "twoHundredDayAverage": 2.0676, "currency": "USD", "enterpriseValue": 98228400, "floatShares": 40313071, "sharesOutstanding": 64450400, "sharesShort": 1590887, "sharesShortPriorMonth": 1559419, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0247, "heldPercentInsiders": 0.0308, "heldPercentInstitutions": 0.53423, "shortRatio": 4.76, "shortPercentOfFloat": 0.0356, "impliedSharesOutstanding": 64450400, "bookValue": 0.597, "priceToBook": 3.6180906, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -36899420, "trailingEps": -0.58, "forwardEps": -0.45, "enterpriseToRevenue": 9822.84, "enterpriseToEbitda": -2.511, "52WeekChange": 0.5, "SandP52WeekChange": 0.21231294, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "GLYC", "underlyingSymbol": "GLYC", "shortName": "GlycoMimetics, Inc.", "longName": "GlycoMimetics, Inc.", "firstTradeDateEpochUtc": 1389364200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "efe04473-e4ee-3464-8e89-48cc4b8490b8", "messageBoardId": "finmb_5703481", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.16, "targetHighPrice": 10.0, "targetLowPrice": 3.0, "targetMeanPrice": 7.0, "targetMedianPrice": 8.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 41792832, "totalCashPerShare": 0.648, "ebitda": -39121992, "totalDebt": 808402, "quickRatio": 6.14, "currentRatio": 6.407, "totalRevenue": 10000, "debtToEquity": 2.104, "returnOnAssets": -0.50546, "returnOnEquity": -0.90724, "freeCashflow": -21877018, "operatingCashflow": -34879904, "grossMargins": 1.0, "operatingMargins": -959.08344, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-19"}]